CORRESP Filing
ALX ONCOLOGY HOLDINGS INC
Date: April 23, 2025 · CIK: 0001810182 · Accession: 0001193125-25-091436
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285620
Letter
Re: ALX Oncology Holdings Inc. Registration Statement on Form S-3 Filed March 6, 2025 File No. 333-285620 Acceleration Request Requested Date: April 24, 2025 Requested Time: 4:05 p.m. Eastern Time, or as soon thereafter as practicable Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, ALX Oncology Holdings Inc. (the “ Company ”) hereby respectfully requests that the above referenced Registration Statement on Form S-3 (File No. 333-285620) (the “ Registration Statement ”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, Professional Corporation, by calling Michael Coke at (650) 565-3596 or Christina Poulsen at (650) 849-3245. Please direct any questions or comments regarding this acceleration request to Michael Coke or Christina Poulsen. [ Signature Page Follows ] AUSTIN BOSTON BOULDER BRUSSELS HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO SALT LAKE CITY SAN DIEGO SAN FRANCISCO SEATTLE SHANGHAI WASHINGTON, DC WILMINGTON, DE
Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, California 94304-1050 O : 650.493.9300 F : 866.974.7329 April 23, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Lauren Hamill
Securities and Exchange Commission April 23, 2025 Page
Sincerely,
ALX Oncology Holdings Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, California 94304-1050 O : 650.493.9300 F : 866.974.7329 April 23, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Lauren Hamill Re: ALX Oncology Holdings Inc. Registration Statement on Form S-3 Filed March 6, 2025 File No. 333-285620 Acceleration Request Requested Date: April 24, 2025 Requested Time: 4:05 p.m. Eastern Time, or as soon thereafter as practicable Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, ALX Oncology Holdings Inc. (the “ Company ”) hereby respectfully requests that the above referenced Registration Statement on Form S-3 (File No. 333-285620) (the “ Registration Statement ”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, Professional Corporation, by calling Michael Coke at (650) 565-3596 or Christina Poulsen at (650) 849-3245. Please direct any questions or comments regarding this acceleration request to Michael Coke or Christina Poulsen. [ Signature Page Follows ] AUSTIN BOSTON BOULDER BRUSSELS HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO SALT LAKE CITY SAN DIEGO SAN FRANCISCO SEATTLE SHANGHAI WASHINGTON, DC WILMINGTON, DE Securities and Exchange Commission April 23, 2025 Page 2 Sincerely, ALX Oncology Holdings Inc. /s/ Harish Shantharam Harish Shantharam Chief Financial Officer cc: Jason Lettmann, ALX Oncology Holdings Inc. Michael Coke, Wilson Sonsini Goodrich & Rosati, Professional Corporation Christina Poulsen, Wilson Sonsini Goodrich & Rosati, Professional Corporation